Tretinoin transdermal - Stiefel Laboratories

Drug Profile

Tretinoin transdermal - Stiefel Laboratories

Alternative Names: Tretinoin Liquipatch

Latest Information Update: 24 Aug 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stiefel Laboratories
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids; Small molecules
  • Mechanism of Action Protein synthesis inhibitors; Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Acne

Most Recent Events

  • 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
  • 28 Dec 2006 Connetics Corporation has been acquired and merged into Stiefel Laboratories
  • 09 Apr 2003 Preclinical data presented at the 61st Annual Meeting of the American Academy of Dermatology (AAD-2003) has been added to the Antibacterial pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top